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Abstract
Background: Preoperative anxiety is known to be related with the postoperative outcomes, although it remains unclear whether
pharmacologic anxiolysis preoperatively leads to better postanesthesia recovery. Hence, the purpose of this study was to assess
whether midazolam premedication would result in improved Quality of Recovery-40 survey scores, as a postoperative recovery
parameter, in female patients undergoing mastectomy.
Methods: This randomized double-blind study was performed at Severance Hospital, Yonsei University Health System, Seoul,
Republic of Korea. Eighty-two females undergoing breast cancer surgery with propofol-remifentanil anesthesia were enrolled and
randomized to receive midazolam 0.02mgkg1 (group M) or saline (group C). Anesthesia was conducted with total intravenous
anesthesia using propofol and remifentanil. On postoperative day 1, the Quality of Recovery-40 survey scores were surveyed.
Results: The global Quality of Recovery-40 survey scores on postoperative day 1 did not signiﬁcantly differ between groups M and
C (183 vs 181, P=0.568). However, the induction time was signiﬁcantly shorter in group M (3.2 vs 4.5min, P<0.001), as was the
total intraoperative propofol consumption (705 vs 1004mg; P=0.022).
Conclusion:Midazolam premedication does not seem to improve the postoperative quality of recovery, though group M showed
faster induction and less propofol consumption.
Abbreviations: BIS = bispectral index, NaCl = sodium chloride, PACU = postanesthesia care unit, POD = postoperative day,
QoR-40 = quality of recovery 40, TCI = target controlled infusion, TIVA = total intravenous anesthesia.
Keywords: mastectomy, midazolam, premedication, quality of recovery1. Introduction
It is well known that high levels of preoperative stress or anxiety
negatively impacts postoperative recovery.[1] Meanwhile, pre-
medication is commonly used for patients experiencing anxiety
before anesthesia and surgery,[2] with midazolam considered 1
reliable premedication drug because of its short-acting, depend-
able effects of sedation, anxiolysis, and meaningful retrograde
amnesia, with few adverse effects.[3] Therefore, anxiolysis with
midazolam premedication can be assumed to result in betterEditor: Kazuo Hanaoka.
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1functional recovery after anesthesia and surgery, although this
assumption has not been fully examined.[4,5]
Regarding the evaluation of postoperative functional recovery,
themost widely usedmethod is theQuality of Recovery 40 (QoR-
40) survey. The high test–retest reliability, internal consistency,
and split-half coefﬁcient of the QoR-40 have led to its recognition
as a useful and practical survey method, and its use has been
validated for various patients undergoing diverse surgical
procedures.[6] Moreover, the effects of some particular premed-
ication drugs such as dexamethasone and gabapentin have also
been evaluated by the QoR-40, though none of these drugs aim at
anxiety reduction.[7–9] In fact, research on recovery scores
associated with anxiolytics is scarce.
Herein, we hypothesized that midazolam premedication for
anxiolysis before anesthesia would affect postanesthesia recov-
ery. Accordingly, females undergoing breast cancer surgery with
propofol-remifentanil anesthesia were enrolled, and we aimed to
compare the QoR-40 as a postoperative recovery parameter
between patients premedicated with midazolam and those
administered saline.
2. Methods
This prospective randomized double-blind study was performed
from September 2013–August 2014 at Severance Hospital,
Yonsei University Health System, Seoul, Republic of Korea. The
protocol was approved by the institutional review board (IRB
Kim et al. Medicine (2017) 96:7 Medicinenumber 4-2013-0444) and the study was registered as a clinical
trial (NCT01945476).2.1. Study population
Written informed consent was obtained from all patients before
enrolment. Females aged 20 to 65 years with an American Society
of Anesthesiologists physical status of 1–2, scheduled to undergo
elective partial or total mastectomy under general anesthesia were
considered eligible. Patients taking medications with central
nervous system effects, such as sedatives and sleeping pills, and
those who reported drinking more than 1 bottle of alcohol/day
were excluded. Additional exclusion criteria were body mass
index >30kg m2, known propofol allergy, and simultaneously
scheduled autologous muscle reconstruction surgery.2.2. Study design
We conducted a randomized, parallel group, double-blind study.
The patients were randomly allocated to the midazolam premed-
ication group (groupM) or the control (NaCl 0.9%) group (group
C) on the morning of the operation using a random number
generator (http://www.random.org/). The ratio of allocation was
1:1. The assignments were concealed in a sealed envelope; the
randomization was not blocked or stratiﬁed. Patients in group M
received 0.02mg kg1 midazolam in 5mL normal saline and those
in groupCreceived anequivalent volume (5mL)of saline only.The
researcher, who did not participate in the conduction of anesthesia
or the postanesthesia surveys, prepared the study drugs. All study
drugs were labeled as “premedication drug” to ensure blinding of
the attending anesthesiologists, the investigator who administered
the QoR-40 survey, and the patients.2.3. Procedure and intervention
The study drugs were administered 30minutes before entering
the operating room, and the patients were monitored for
respiratory rate and peripheral oxygen saturation in the
pretreatment room immediately after administration. Supple-
mental oxygenwas provided if a patient’s respiratory rate was<8
breaths min1 or if the peripheral oxygen saturation was <92%.
Upon arrival to the operating room, routine monitoring,
including electrocardiography, pulse oximetry, noninvasive
blood pressure, bispectral index (BIS) monitoring, and capnog-
raphy were applied. All patients received total intravenous
anesthesia (TIVA) with an effect-site target controlled infusion
(TCI) of propofol and remifentanil, which was prepared with 2%
propofol (Fresofol 2% injection 50 mL vial; Fresenius Kabi,
Austria) and 20mg mL1 remifentanil (Ultiva injection 1mg vial;
GlaxoSmithKline, Belgium). A commercially available TCI pump
(Orchestra Base Primea; Fresenius Vial, France) was used. The
effect-site TCI for propofol was based on Schnider’s pharmaco-
kinetic model and that for remifentanil on the model by Minto
and colleagues.[10,11] Anesthesia was induced with remifentanil
3mg mL1 followed by propofol 3mg mL1 initially, and the
propofol concentration was adjusted every 30seconds until the
patient lost consciousness, after which 0.6mg kg1 rocuronium
was administered to facilitate intubation. Tracheal intubation
was performed in all patients using a 6.5-mm (internal diameter)
tracheal tube, and the cuff pressure was maintained at 20 to 25
cmH2O. Mechanical ventilation was maintained with a tidal
volume of 8mL kg1 ideal body weight, and the ventilator
frequency was adjusted to maintain an end-tidal carbon dioxide2concentration of 35 to 40mm Hg using an air/oxygen mixture
(fraction of inspired oxygen, 0.5). The body temperature was
maintained at 36 to 37°C. During the surgical procedure,
propofol was titrated to maintain BIS values of 40 to 60 and
remifentanil was adjusted to keep the blood pressure and heart
rate within 20% of the baseline values. Approximately 30
minutes before operation completion, propacetamol 20mg kg1
was administered over 10 minutes, and 1mg kg1 of fentanyl and
0.3mg ramosetron were injected approximately 15 minutes
before the end of the surgery. The propofol and remifentanil
infusions were discontinued upon surgery completion, and the
patients were administered 30mg kg1 of neostigmine with 6mg
kg1 of glycopyrrolate to reverse any residual neuromuscular
blockade.When consciousness and spontaneous respiration were
adequately restored, the endotracheal tube was removed and the
patient was transferred to the post anesthesia recovery unit
(PACU). The patients were transferred to the ward after at least
30minutes in the PACU when they fulﬁlled the discharge criteria
according to the modiﬁed Aldrete scoring system (score ≥ 9, with
no score of 1 in any individual category).[12]2.4. Assessment of outcomes
2.4.1. Primary outcomes. A single researcher who was
unaware of the group assignments visited each patient before
the surgery and on postoperative day 1 (POD 1), between 6 and 8
pm, to conduct the QoR-40 surveys. The global QoR-40 score on
POD 1 was the primary endpoint of this study. The QoR-40
measures 5 general quality of life dimensions: physical comfort
(12 items), emotional state (9 items), physical independence (5
items), psychological support (7 items), and pain (7 items). Each
item is graded on a 5-point Likert scale, and the global score
ranges from 40 (extremely poor quality of recovery) to 200
(excellent quality of recovery). The QoR-40 scoring system was
explained in detail to all participants and the questionnaire was
completed in the presence of the researcher and reviewed to
ensure accurate comprehension of all questions.
2.4.2. Secondary outcomes. The sedation scores (1–5) were
recorded in the pretreatment room and PACU. Sedation scores of
1, 2, 3, 4, and 5 indicated that the patient was completely awake,
partly asleep, responsive to vocal commands but seemed asleep,
showed signs of sleeping and reacted to vocal commands more
slowly, and seemed to be asleep and did not react to vocal
commands, but did react to stimulation, respectively.[13]
During anesthesia induction, we recorded the effect-site
concentration and total infused amount of propofol required
and the times to loss of consciousness and BIS < 60. The total
amount of propofol and remifentanil infused during anesthesia,
and the surgical and anesthesia durations were also recorded.
To determine the recovery time from anesthesia, we measured
the effect-site concentration of propofol and the time from
stopping the anesthetic infusion to response to verbal commands,
as well as the effect-site concentration of propofol and the time to
removal of the endotracheal tube.
During the stay in the PACU, we used the numeric rating scale
with a 0 (no pain) to 10 (worst pain imaginable) scoring system to
evaluate the immediate postoperative pain. We recorded the pain
scores, nausea, and vomiting events, and any other symptoms
reported by the patients as well as any medications that were
given to relieve the symptoms. Once the patients were in a ward,
we recorded the analgesic requirements during the initial 24
postoperative hours, occurrence of nausea and/or vomiting, total
antiemetic requirement, and length of hospital stay.
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Considering a number of previous reports that regarded an
average difference of ≥10 in the QoR-40 scores as signiﬁcant and
that demonstrated that women who undergo general anesthesia
scored an average of 162 on the QoR-40, along with an alpha of
0.05, and power of 90%,[6,14] we determined that 34 patients per
group were required. Therefore, considering a case loss of 20%,
we planned to collect data from 41 patients per group.
Data analysis was based on the intent-to-treat approach. We
tested every hypothesis at a 5% signiﬁcance level and principally
conducted a dual-examination. Shapiro-Wilk and Kolmogorov–-
Smirnov tests were performed to assess the hypothesis of normal
distribution. All continuous variables are expressed as the mean
(± standard deviation) or median (interquartile range), and all
nominal factors as n (proportion, %). We performed Student’s t-
test or the Mann–Whitney U test for inter-group comparisons of
the QoR-40 scores and other continuous variables. Additionally,
the paired t-test or Wilcoxon signed rank test was used to
compare the intra-group differences in the global and dimension
QoR-40 scores preoperatively and on POD 1. Nominal variables
were compared using the Chi-square and Fisher’s exact tests. We
used SPSS version 23 (SPSS, Inc., Chicago, IL) for the statistical
analyses, with P<0.05 indicating statistical signiﬁcance.3. Results
3.1. Study population
A total of 91 patients were assessed for eligibility, of whom 82
patients were included. Among them, 1 patient was withdrawn
due to a change in the surgical plan during operation. Thus, we
ﬁnally collected and analyzed data from 81 patients within
hospital stay. And, there were no signiﬁcant differences between
the groups in terms of the patient characteristics (Table 1).3.2. Primary outcome
Table 2 shows the global and dimensional (emotional state,
physical comfort, psychological support, physical independence,
and pain) QoR-40 scores on POD 1. The baseline preoperative
global and dimensional QoR-40 scores did not differ signiﬁcantly
between groups M and C (179 vs 180, P=0.784), nor were there
any signiﬁcant differences in the global and dimensional QoR-40
scores on POD1 (181 vs 183, P=0.568). The subscores for theTable 1
Characteristics of the study patients.
Group C (n=41)
Age, y 48 (44.5–55 [33–65])
Height, cm 159 (157–163 [145–170])
Weight, kg 58.2 (54–62.4 [44–80])
ASA physical status
1 24 (58.5%)
2 19 (46.3%)
Adjuvant chemotherapy 11 (26.8%)
Surgical procedures
Partial mastectomy 33 (80.5%)
Total mastectomy 5 (12.2%)
MRM 3 (7.3%)
The values are expressed as the median (interquartile range, [minimum-maximum]) or number (%).
There were no signiﬁcant differences between the midazolam premedication group and the control gro
ASA=American Society of Anesthesiologists, MRM=modiﬁed radical mastectomy.
3QoR-40 dimensions of emotional state and psychological
support were improved on POD1 compared with the preopera-
tive values in both study groups according to the intra-group
comparison.3.3. Secondary outcome
Table 3 presents the perioperative data. The sedation score was
signiﬁcantly higher before induction (2 vs 1), the time to loss of
consciousness was faster (1.5 vs 3.3 s), and loss of consciousness
was achieved at a lower concentration (3 vs 4.1mg) and dose
(58.9 vs 96mg) of propofol in group M compared with in group
C. Further, the intraoperative propofol consumption was lower
in group M compared with in group C (705 vs 1004mg, P=
0.022).
The postoperative recovery parameters examined in the PACU
are described in Table 4. The sedation scores did not signiﬁcantly
differ between the groups at admission or at discharge from the
PACU. The pain scores were signiﬁcantly lower in group M at
discharge from PACU (P=0.004), though there were no
signiﬁcant differences in terms of analgesic requirements. There
were also no signiﬁcant differences in the analgesic and
antiemetic requirements on POD 1, or in the length of hospital
stay between the 2 groups.4. Discussion
Our results demonstrated that midazolam premedication did not
signiﬁcantly affect patient-reported quality of recovery on POD 1
in female patients after mastectomy under general anesthesia with
propofol–remifentanil. The dimensions of the QoR-40 subcom-
ponent-scores also did not differ between patients receiving
midazolam premedication or not.
All kinds of efforts for better quality of recovery should be
performed to ensure the patients’ satisfaction and well-being.
Better quality of recovery does not only rely on the postoperative
analgesia and on postoperative nausea and vomiting control, but
also on intraoperative treatments such as the appropriate
anesthetic method or main anesthetic agents,[15] addition of
adjuvants to prevent postoperative complications,[8,16–18] or
adoption of new surgical procedures.[19] Of course, such efforts
should be planned for during the preoperative period already.
Although some preoperative medication or treatments have been
reported to be associated with an improvement in the quality ofGroup M (n=40) P
49 (41.3–56 [26–64]) 0.853
159.5 (154.3–163 [140–173]) 0.606
57.5 (52–63 [43–71]) 0.396
0.492
27 (67.5%)
13 (32.5%)
9 (22.5%) 0.798
0.611
30 (75%)
7 (17.5%)
3 (7.5%)
up regarding the patients’ characteristics and underlying status.
[20,21]
Table 2
The global and dimensional QoR-40 scores.
Group C (n=41) P
∗
Group M (n=40) P† P‡
QoR-40 dimensions
Emotional state <0.001 0.002
Preoperative 38 (34.5–41 [26–45]) 38 (31.5–42 [20–45]) 0.946
Postoperative day 1 40 (38–42.5 [27–45]) 40 (38–43 [28–45]) 0.366
Physical comfort 0.182 0.184
Preoperative 55 (50–57.5 [18–60]) 55 (51.5–57.5 [26–59]) 0.801
Postoperative day 1 56 (51.5–57 [24–60]) 56 (53–58 [25–60]) 0.638
Psychological support 0.004 0.05
Preoperative 30 (27.5–34.5 [17–35]) 32 (26–35 [20–35]) 0.947
Postoperative day 1 32 (29.5–34 [23–35]) 32 (29.5–35 [16–35]) 0.693
Physical independence 0.001 0.001
Preoperative 25 (23–25 [22–25]) 25 (23–25 [18–25]) 0.854
Postoperative day 1 23 (23–24 [22–25]) 23 (23–24 [19–25]) 0.700
Pain 0.001 0.001
Preoperative 33 (31–34 [26–35]) 33 (31–34.5 [20–35]) 0.853
Postoperative day 1 31 (29–32 [20–35]) 31 (29–32 [20–35]) 0.738
Global QoR-40 0.241 0.169
Preoperative 179 (170–188.5 [131–196]) 180 (170.5–188.5 [125–195]) 0.784
Postoperative day 1 181 (175.5–187 [154–197]) 183 (176.5–187 [150–192]) 0.568
Values are expressed as the median (interquartile range, [minimum-maximum]).
∗
P values demonstrate the results from the Wilcoxon signed rank test in group C.
†P values demonstrate the results from the Wilcoxon signed rank test in group M.
‡P values demonstrate the results from the Mann-Whitney U test between groups M and C.
QoR-40=Quality of Recovery 40 survey.
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anxiety should not be overlooked in this aspect.
Preoperative anxiety has been reported to be associated with
poor postoperative behavioral and clinical recoveries.[22,23]
Additionally, anxiety is the most common predictor for
postoperative pain,[24] and higher levels of preoperative anxiety
are associated with an increased incidence of emesis.[25]
Intravenous midazolam as premedication has been shown to
reduce the incidence of postoperative nausea, with a trend toward
less postoperative vomiting for up to 24hours postoperatively,[7]
and women administered intramuscular benzodiazepines 30
minutes before abdominal hysterectomy showed beneﬁcial effects
on postoperative analgesic requirements in 1 previous study,[2]
supporting the assumption that preoperative anxiolysis could
lead to improved quality of recovery.
Moreover, a considerable degree of psychological distress
might be expected especially in females undergoing breast cancer
surgery, both due to the diagnosis and the anticipated alterations
in body image.[26,27] In addition, preoperative anxiety is generally
maximized before transfer to the operating room.[28] Therefore,
premedication with anxiolytics targeting this moment in female
patients undergoing mastectomy is thought to result in improved
postoperative recovery.
However, the present study did not show any differential
effects of midazolam premedication on the QoR-40 score.
Several reasons may account for this result. First, postanesthetic
recovery seems to be signiﬁcantly inﬂuenced by the anesthesia
method. TIVA with propofol and remifentanil has been shown
to have superior effects to volatile anesthetics in terms of
reduced postoperative nausea, vomiting, and pain.[29,30] In our
recent study, female patients undergoing thyroid surgery
randomized to the TIVA group perceived a better quality of
recovery on POD1 and POD 2 compared with patients in the
desﬂurane group.[15] Hence, the advantage of TIVA with
propofol and remifentanil might conceal any beneﬁcial effects
of midazolam premedication.4The next consideration relates to the type of surgery.
Mijderwijk and colleagues[5] found that lorazepam, the most
potent benzodiazepine, had no beneﬁcial effects on the quality of
recovery or on the manifestations of resistance in outpatients.
These authors speculated that their result may have been related
to the speciﬁc characteristics of outpatients and proposed that
their study should be repeated in hospitalized patients undergo-
ing major surgery whomay be facing a longer stay in the hospital.
However, even though the patients undergoing mastectomy are
supposed to have a higher level of anxiety, mastectomy itself is
not only a relatively minor surgery but also requires only a short
in-hospital stay. Therefore, the physiologic disturbance immedi-
ately after surgery might not be signiﬁcant in our study patients.
Furthermore, in another previous study, compared with no
premedication or placebo, the anxiolytic premedication with
lorazepam did not enhance the self-reported patient experience
the day after elective surgery with general anesthesia, but was
related to the delayed time to extubation and decreased rate of
cognitive recovery in the postoperative early phase.[31] These
ﬁndings suggest that long/intermediate-lasting anxiolytic medi-
cations, including benzodiazepines (e.g., lorazepam), should no
longer be considered the standard premedication.
Lastly, there are various manifestations of preoperative
anxiety. We considered that preoperative anxiety would reach
its peak immediately before anesthesia induction and surgery.
However, according to our interviews, many patients were more
anxious about their cancer diagnosis than the surgery, and they
often felt better postoperatively, owing to relief that the cancer
had been removed. Consequently, pharmacologic premedication
immediately before surgery might not be sufﬁcient to relieve all
anxiety and stress in these patients, and may hence also be
insufﬁcient to achieve better quality of recovery after anesthesia
and surgery.
Of note, our study did not show any adverse effect from
midazolam premedication, and the patients who received
midazolam required smaller doses of the anesthetic agent and
Table 4
Postoperative recovery proﬁles.
Group C (n=41) Group M (n=40) P
In the PACU
Admission
Sedation score 2 (1–2 [0–5]) 1.5 (1–2 [0–5]) 0.164
Pain NRS 1 (1–2.5 [1–3]) 1 (1–2.8 [1–3]) 0.934
Discharge
Sedation score 1 (1–1 [1–2]) 1 (1–1 [1–2]) 0.599
Pain NRS 2 (2–3 [1–3]) 2 (1–2 [1–4]) 0.004
Analgesics requirement 11 (26.8%) 17 (42.5%) 0.165
Antiemetic requirement 0 0 1.000
Length of stay, min 45 (30–40 [38–70]) 50 (30–50 [30–100]) 0.076
In a ward
Analgesics requirement 32 (78%) 28 (70%) 0.455
Antiemetic requirement 8 (19.5%) 8 (20%) >0.999
Postoperative hospital stay, days 2 (2–2 [1–4]) 2 (2–2 [1–7]) 0.755
Values are expressed as the median (interquartile range, [minimum – maximum]) or number (%).
The pain NRS when leaving the PACU was statistically lower in the midazolam premedication group than in the control group. Other parameters were not signiﬁcantly different.
NRS=numeric rating scale, PACU=post an aesthetic care unit.
Table 3
Perioperative data.
Group C (n=41) Group M (n=40) P
Sedation score after midazolam administration 1 (1–1 [1–2]) 2 (2–2 [1–2]) <0.001
Initial vital signs
MBP, mm Hg 97 (85–104 [64–122]) 89.5 (80.3–104.8 [64–128]) 0.431
PR, beats.min1 79 (68.5–93.5 [55–109]) 75 (65.3–90.5 [48–111]) 0.398
Induction
Not responding to verbal commands
Time, min 3.3 (2–4 [1–7]) 1.5 (1.2–2 [1–4]) <0.001
Propofol concentration, mg 4.1 (3.7–4.8 [2–6]) 3 (2.8–3.8 [2–5]) <0.001
Propofol dose, mg 96 (69.6–105 [42–172]) 58.9 (49.0–67.7 [39–116]) <0.001
Remifentanil concentration, ng 3 (3–3 [2–4]) 3 (3–3 [3–3]) 0.314
Remifentanil dose, mg 74 (59.6–81.2 [47–120]) 55.4 (51.5–61.3 [44–87]) <0.001
Intubation
Time, min 4.5 (3–6.8 [2–11]) 3.2 (1.9–4.4 [1–18]) <0.001
Propofol concentration, mg 4.5 (3.9–6.8 [2–6]) 3.3 (3–4 [3–5]) <0.001
Propofol dose, mg 105 (82.4–157 [52–235]) 70.3 (59.9–99.4 [39–226]) <0.001
Remifentanil concentration, ng 3 (3–3 [2–5]) 3 (3–3 [2–4]) 0.885
Remifentanil dose, mg 81.3 (66.9–99.5 [49–186]) 66.1 (55.5–88.5 [3–147]) <0.001
Emergence
Responding to verbal commands
Time, min 4.8 (3–7 [1–12]) 4 (2.6–6.9 [0.5–9.5]) 0.476
Propofol concentration, mg 1.1 (1–1.3 [1–2]) 1 (0.8–1.2 [1–2]) 0.128
Remifentanil concentration, ng 0.6 (0.5–1.1 [0–3]) 0.8 (0.5–1.0 [0–2]) 0.311
BIS score 73 (66–76.5 [59–86]) 74.5 (64.3–77.8 [58–88]) 0.805
Extubation
Time, min 6 (4.5–8 [2–18]) 5 (3.7–7.3 [1–15]) 0.281
Propofol concentration, mg 1 (0.9–1.2 [1–2]) 0.9 (0.7–1.1 [1–2]) 0.075
Remifentanil concentration, ng 0.5 (0.4–0.9 [0–2]) 0.6 (0.4–0.9 [0–2]) 0.420
BIS score 81 (76–85 [72–90]) 80 (78–85 [73–91]) 0.704
Propofol consumption, mg 1004 (681–1217.5 [350–2070]) 705 (546.8–1053 [66–1664]) 0.022
Remifentanil consumption, mg 713 (588–1008 [341–2056]) 680 (495.5–1027.5 [345–1700]) 0.266
Administered ﬂuid, mL 600 (450–675 [250–1100]) 625 (462.5–787.5 [200–1700]) 0.472
Estimated blood loss, mL 10 (0–50 [0–200]) 16.5 (0–50 [0–100]) 0.905
Anesthetic duration, min 130 (115–162.5 [85–275]) 122.5 (96.3–168.8 [75–260]) 0.409
Surgical duration, min 110 (90–137.5 [60–240]) 97.5 (75–145 [50–225]) 0.422
Values are expressed as the median (interquartile range, [minimum – maximum]) or number (%).
BIS=bispectral index, MBP=mean blood pressure, PR=pulse rate.
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Kim et al. Medicine (2017) 96:7 Medicinepropofol and had shorter induction time compared with the
subjects who received saline. These results are in agreement with
previous reports, where premedication has been associated with a
lower likelihood of the stormy induction of anesthesia associated
with arterial desaturation.[31] Furthermore, the anesthetic and
analgesic doses can be modiﬁed according to the patients’ pain
sensitivity and preoperative anxiety levels,[32] and the addition of
midazolam to a combination of opioids and propofol has been
reported to be associated with a 71% reduction in effective site
concentration.[33]
There are some limitations to the present study. First, it may be
argued that a higher dose of midazolam might lead to deeper
sedation and different results. However, a previous study
demonstrated that a midazolam dose of 0.02mg kg1 was
sufﬁcient for producing sedation and anxiolysis with minimal
effects on the cardiorespiratory status.[3] On the other hand, a
higher dose carries a higher risk of paradoxical reaction,
hemodynamic changes, and respiratory depression[34] and would
not have been suitable for the aims of our study. Second, we only
used a sedation scale in this study, rather than an anxiety scale
such as the State-Trait Anxiety questionnaire.[5] However, the
anxiolytic effects of midazolam with this dose have been well
documented already,[1,4,5] and the main focus of our study was
the functional recovery after surgery.
5. Conclusions
Our ﬁndings suggest that premedication with 0.02mg kg1
intravenous midazolam did not affect the postoperative QoR-40
recovery scores in female patients undergoing propofol-remi-
fentanil anesthesia during in-hospital mastectomy. However, this
premedication was associated with shorter induction times and
lower total anesthetic consumption.More advanced studies, with
more comprehensive anxiolytic regimens, administered during
the entire preoperative period, and under more complex
surgeries, are warranted in the future.References
[1] Kain ZN, Sevarino F, Pincus S, et al. Attenuation of the preoperative
stress response with midazolam: effects on postoperative outcomes.
Anesthesiology 2000;93:141–7.
[2] Kain ZN, Sevarino FB, Rinder C, et al. Preoperative anxiolysis and
postoperative recovery in women undergoing abdominal hysterectomy.
Anesthesiology 2001;94:415–22.
[3] Sun GC, Hsu MC, Chia YY, et al. Effects of age and gender on
intravenous midazolam premedication: a randomized double-blind
study. Br J Anaesth 2008;101:632–9.
[4] Bauer KP, Dom PM, Ramirez AM, et al. Preoperative intravenous
midazolam: beneﬁts beyond anxiolysis. J Clin Anesth 2004;16:177–83.
[5] Mijderwijk H, van Beek S, KlimekM, et al. Lorazepam does not improve
the quality of recovery in day-case surgery patients: a randomised,
placebo-controlled clinical trial. Eur J Anaesthesiol 2013;30:743–51.
[6] Myles PS, Weitkamp B, Jones K, et al. Validity and reliability of a
postoperative quality of recovery score: the QoR-40. Br J Anaesth
2000;84:11–5.
[7] Murphy GS, Szokol JW, Greenberg SB, et al. Preoperative dexametha-
sone enhances quality of recovery after laparoscopic cholecystectomy:
effect on in-hospital and postdischarge recovery outcomes. Anesthesiol-
ogy 2011;114:882–90.
[8] Kim SH, Oh YJ, Park BW, et al. Effects of single-dose dexmedetomidine
on the quality of recovery after modiﬁed radical mastectomy: a
randomised controlled trial. Minerva Anestesiol 2013;79:1248–58.
[9] White PF, Tufanogullari B, Taylor J, et al. The effect of pregabalin on
preoperative anxiety and sedation levels: a dose-ranging study. Anesth
Analg 2009;108:1140–5.
[10] Schnider TW, Minto CF, Gambus PL, et al. The inﬂuence of method of
administration and covariates on the pharmacokinetics of propofol in
adult volunteers. Anesthesiology 1998;88:1170–82.6the pharmacokinetics and pharmacodynamics of remifentanil. I. Model
development. Anesthesiology 1997;86:10–23.
[12] White PF, Song D. New criteria for fast-tracking after outpatient
anesthesia: a comparison with the modiﬁed Aldrete’s scoring system.
Anesth Analg 1999;88:1069–72.
[13] Paris A, Kaufmann M, Tonner PH, et al. Effects of clonidine and
midazolam premedication on bispectral index and recovery after elective
surgery. Eur J Anaesthesiol 2009;26:603–10.
[14] De Oliveira GSJr, Ahmad S, Fitzgerald PC, et al. Dose ranging study on
the effect of preoperative dexamethasone on postoperative quality of
recovery and opioid consumption after ambulatory gynaecological
surgery. Br J Anaesth 2011;107:362–71.
[15] Lee WK, Kim MS, Kang SW, et al. Type of anaesthesia and patient
quality of recovery: a randomized trial comparing propofol-remifentanil
total i.v. anaesthesia with desﬂurane anaesthesia. Br J Anaesth 2015;
114:663–8.
[16] De Oliveira GSJr, Duncan K, Fitzgerald P, et al. Systemic lidocaine to
improve quality of recovery after laparoscopic bariatric surgery: a
randomized double-blinded placebo-controlled trial. Obes Surg
2014;24:212–8.
[17] Kim SY, Kim JM, Lee JH, et al. Efﬁcacy of intraoperative dexmede-
tomidine infusion on emergence agitation and quality of recovery after
nasal surgery. Br J Anaesth 2013;111:222–8.
[18] Kane SM, Garcia-Tomas V, Alejandro-Rodriguez M, et al. Randomized
trial of transversus abdominis plane block at total laparoscopic
hysterectomy: effect of regional analgesia on quality of recovery. Am
J Obstet Gynecol 2012;207:419e 411–5.
[19] Park YH, KimKT, Ko K, et al. Prospective randomized controlled trial of
conventional laparoscopic versus laparoendoscopic single-site radical
nephrectomy for localized renal cell carcinoma: a preliminary report
regarding quality of life. World J Urol 2015;33:367–72.
[20] Pauls RN, Crisp CC, Oakley SH, et al. Effects of dexamethasone on
quality of recovery following vaginal surgery: a randomized trial. Am J
Obstet Gynecol 2015;213:718 e711–7.
[21] Mariappan R, Mehta J, Massicotte E, et al. Effect of superﬁcial cervical
plexus block on postoperative quality of recovery after anterior cervical
discectomy and fusion: a randomized controlled trial. Can J Anaesth
2015;62:883–90.
[22] Johnston M. Pre-operative emotional states and post-operative recovery.
Adv Psychosom Med 1986;15:1–22.
[23] Kiecolt-Glaser JK, Page GG, Marucha PT, et al. Psychological inﬂuences
on surgical recovery. Perspectives from psychoneuroimmunology. Am
Psychol 1998;53:1209–18.
[24] Ip HY, Abrishami A, Peng PW, et al. Predictors of postoperative pain and
analgesic consumption: a qualitative systematic review. Anesthesiology
2009;111:657–77.
[25] Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology,
treatment, and prevention. Anesthesiology 1992;77:162–84.
[26] Fox JP, Philip EJ, Gross CP, et al. Associations between mental health
and surgical outcomes among women undergoing mastectomy for
cancer. Breast J 2013;19:276–84.
[27] Arsalani-Zadeh R, ElFadl D, Yassin N, et al. Evidence-based review of
enhancing postoperative recovery after breast surgery. Br J Surg
2011;98:181–96.
[28] McCleane GJ, Cooper R. The nature of pre-operative anxiety.
Anaesthesia 1990;45:153–5.
[29] Gupta A, Stierer T, Zuckerman R, et al. Comparison of recovery proﬁle
after ambulatory anesthesia with propofol, isoﬂurane, sevoﬂurane and
desﬂurane: a systematic review. Anesth Analg 2004;98:632–41. table of
contents.
[30] Tan T, Bhinder R, CareyM, et al. Day-surgery patients anesthetized with
propofol have less postoperative pain than those anesthetized with
sevoﬂurane. Anesth Analg 2010;111:83–5.
[31] Axel MS, Pascal A, Veronique VO, et al. Effect of sedative premedication
on patient experience after general anesthesia: a randomized clinical trial.
JAMA 2015;313:916–25.
[32] Abdul-Latif MS, Putland AJ, McCluskey A, et al. Oral midazolam
premedication for day case breast surgery, a randomised pros-
pective double-blind placebo-controlled study. Anaesthesia 2001;56:
990–4.
[33] OlmosM, Ballester JA, VidarteMA, et al. The combined effect of age and
premedication on the propofol requirements for induction by target-
controlled infusion. Anesth Analg 2000;90:1157–61.
[34] Conway DH, Hasan SK, Simpson ME. Target-controlled propofol
requirements at induction of anaesthesia: effect of remifentanil and
midazolam. Eur J Anaesthesiol 2002;19:580–4.
